Brain and Behavior. 2018;8:e00995.
1 of 5
1 | INTRODUCTION
Parkinson’s disease (PD) is the second most common neurode-
generative disease in the world, second only to Alzheimer’s dis-
ease (Toulouse & Sullivan, 2008). Clinical manifestations of PD
include both motor and nonmotor symptoms. Muscle rigidity,
resting tremor, slow movement, and postural disorders (Poewe
et al., 2017) are the main motor symptoms and the nonmotor
symptoms include disorder of sensation, sleep, emotion, cogni-
tion, and autonomic nerve and so on. Relja (2012) reported that
Ceruloplasmin in Parkinson’s disease and the nonmotor
| Ziqiang Shao
| Yu Zhang
| Fang Liu
| Zhibo Liu
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2018 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
Department of Radiology, The First Hospital
of Tsinghua University, Beijing, China
Department of Neurology, China-Japan
Friendship Hospital, Beijing, China
The School of Medicine, Tsinghua
University, Beijing, China
Department of Neurology, The First
Hospital of Tsinghua University, Beijing,
Ziqiang Shao, Department of Neurology,
China-Japan Friendship Hospital, Beijing,
Objectives: To investigate the relationship between ceruloplasmin (CP) and
Parkinson’s disease (PD), and the correlation between CP level and the time differ-
ence between nonmotor symptoms and motor symptoms and the diagnosis were
Materials and Methods: Sixty- six patients diagnosed with PD for the first time were
included in the study. They were divided into CP reduction group (31 cases) and CP
normal group (35 cases) according to their CP level. The estimated time difference
between nonmotor symptoms and motor symptoms and the diagnosis were recorded
respectively. The magnetic sensitive nigra phase value was measured by susceptibil-
ity weighted imaging (SWI).
Results: Ceruloplasmin level was middling correlated with age (r = .561, p < .001).
There was strong negative correlation between CP level and UPDRS scores (r=−.727,
p < .001). The CP level was significantly correlated with the magnetic sensitive nigra
phase value (r = .891, p < .001). CP level showed moderate correlation with the time
difference from nonmotor symptoms to motor symptoms (r = .559, p < .001), besides,
the time difference between nonmotor symptoms and the diagnosis (r = .525,
p < .001) and CP level was also moderately related.
Conclusions: Ceruloplasmin interference in iron metabolism was closely related with
PD development. And there were slight corrections between CP level and the time
difference from nonmotor symptoms to motor symptoms or the diagnosis.
ceruloplasmin, motor symptoms, nonmotor symptoms, Parkinson’s disease